News

Jessica MacIntyre, executive director of clinical operations at Sylvester Comprehensive Cancer Center, explains how the small market for experienced oncology nurse practitioners prompted their institution to design a successful Hematology/Oncology Nurse Practitioner Fellowship.

The director at the Center for Cancer Health Equity, The University of Ohio Comprehensive Cancer Center, discusses how the pandemic put a spotlight on issues of equity within the health care system.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, discusses omacetaxine as a novel regimen in CML treatment.

A survey completed by nurses and APPs revealed that many healthcare professionals may be blind to their own implicit biases.

The director at the Center for Cancer Health Equity, The University of Ohio Comprehensive Cancer Center, discusses improving preventative screenings in underprivileged communities.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, comments on how health care providers can effectively care for patients with COVID-19 and hematologic malignancies.

Answering questions without judgement and showcasing community members who have received the COVID-19 vaccine without negative outcomes can help alleiviate vaccine-related fears and concerns in BIPOC patients with cancer.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, comments on the dedication she has observed from caregivers taking care of loved ones with leukemia during the COVID-19 era.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News Co-Editor in Chief, shares her opinion on recent developments in leukemia treatment options.

Between monitoring for medication adherence and ensuring that patients know when to call if their symptoms escalate, oncology nurses are a pivotal factor in decreasing mortality among patients with leukemia, says Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN.

Chevon Rariy, MD, outlines patient eligibility criteria, and the alterations to the nurse patient relationship, as CTCA launches the novel Oncology Clinic at Home Program.

Nagla Abdel Karim, MD, explains how researchers will address safety and manage potential adverse events in the ongoing phase 3 CheckMate-73L trial.

“There were delays in getting preventative screenings, there were delay in diagnostics, there was also a brief period of time when some of the clinical trials were shut down.”

Kelly L. Garvin, BSN, RN, OCN, discusses what changes she hopes to see in CAR T-Cell therapy treatment over the coming years.

“More than 90% of serotonin receptors and serotonin is made in the gut.”

There is far less patient education for oral agents, such as CDK4/6 inhibitors for breast cancer, as there is for chemotherapy. This is a major issue, explained Patricia Jakel, MN, RN, AOCN, advanced practice nurse at UCLA's solid tumor program and co-editor in chief of Oncology Nursing News.

Frequent communication between patients and providers is key in getting ahead of adverse events that can occur during breast cancer treatment, explained Madeline Kuiper, MSN, RN, OCN, an oncology nurse practitioner at UCLA.

An ongoing randomized phase III clinical trial is investigating the safety and efficacy of atezolizumab (Tecentriq) as an adjuvant treatment in patients with high-risk, locally advanced squamous cell carcinoma of the head and neck (SCCHN) after definitive local therapy, compared with placebo.

Children's Brain Tumor Foundation explains the importance of their research and programs.

Rowan Chlebowski, MD, PhD, discusses how losing 5 pounds, as seen in the Women's Intervention Nutrition Study, had a positive impact for breast cancer patients, especially whose disease was triple-negative.

Tim Turnham, executive director, Melanoma Research Foundation, provides an overview of some of the services offered by the Melanoma Research Foundation.